GKB OPHTHALMICS LTD. (GKB)

BSE: ₹64.84
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication

Please find enclosed copies of newspaper cuttings of the extract of statement of audited Standalone and Consolidated Financial Results for the year ended March 31, 2026, published in Free Press Journal (Mumbai Edition) and on Pudhari (Marathi) dated May 29, 2026. Please acknowledge receipt.

2026-06-01 10:51:34
Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2026

Enclosed please find the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. Kindly take the information on record.

2026-05-27 20:34:01
Board Meeting Outcome for GKB_Outcome Of The Board Meeting Held On May 27, 2026

The meeting of the Board of Directors of the Company was held on May 27, 2026 which approved and took on record the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026. Enclosed please find the Outcome of the meeting and the Audited Standalone and Consolidated Financial Results together with the Auditors' Report for the quarter and year ended March 31, 2026 and the Declaration of unmodified opinion from the CFO. The above results are uploaded on the Company's Website at www.gkb.net and on BSE Website at www.bseindia.com. The Board of Directors' Meeting started at 5:45 P.M. and ended at 7:15 P.M., on the same day.

2026-05-27 20:15:42
Announcement under Regulation 30 (LODR)-Credit Rating

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that CRISIL Ratings Limited (" CRISIL Ratings") has migrated the ratings of the Company from "Crisil D issuer Not Cooperating" to "Crisil D" for the bank-based facilities of the Company ,vide their letter dated May 26, 2026. A Copy of the Ratings Rationale issued by CRISIL is enclosed. We request to take the above information on record.

2026-05-27 12:11:29
Compliances-Reg.24(A)-Annual Secretarial Compliance

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, enclosed please find the Annual Secretarial Compliance Report for the year ended March 31, 2026, issued by Ms. Girija Nagvekar, Practicing Company Secretary and Secretarial Auditor of the Company. Kindly take the above information on record.

2026-05-23 15:44:05
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ende March 31, 2026.

the Audited Standalone and Consolidated Financial Results of the company for the qurter and year ended March 31, 2026. The Notice can be accessed at the Company's website at www.gkb.net Further, notice is hereby given with reference to the above meeting of the Board of Directors that the Trading Window for dealing with equity shares of the Company, by designated persons, under the SEBI (Prohibition of Insider Trading) Regulation, 2015, had been closed from April 01, 2026, will now re-open after the completion of 48 hours from the date of submission of financial results to the Stock Exchange. This communication has been sent to all the Directors sand all the designated emplyoyees of the Company.

2026-05-04 11:45:09
Non Applicability Of Circular No. SEBI/HO/DDHS/CIR/P/2018/144, Dated November 26, 2018

Pursuant to Circular no. SEBI/HO/DDHS/CIR/P/2018/144, dated November 26,2018, issued by the securities and Exchange Board of India , we hereby confirm that GKB Ophthalmics Limited, is not a " Large Corporate ", as defined in the said Circular and hence the said Circular is not applicable to us. Kindly take the above information on record.

2026-04-07 12:10:11
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Please find herewith Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations , 2018, for the quarter ended March 31, 2026. Kindly acknowledge receipt of the same.

2026-04-07 12:03:55
Disclosure Under Regulation 31 (4) Of SEBI (Substantial Acquisition Of Shares And Takeover ) Regulation , 2011 For The Financial Year Ended March 31, 2026.

Please find enclosed herewith the disclosure under Regulation 31 (4) of Securities and Exchange Board of India ( Substantial Acquisition of Shares and Takeover ) Regulation 2011 for the financial year ended on March 31, 2026, received from Mr. Krishna Gopal Gupta ( K. G.Gupta ) , Promoter of the Company on behalf of Promoter and Promoter group of the Company. We request you to please take the information on record.

2026-04-02 15:41:02
Closure of Trading Window

Pursuant to SEBI (Prohibition of Insider Trading) Regulation 2015, as amended from time to time , the " Trading Window" for dealing / trading in the shares of the Company shall remain closed from April 01,2026, till completion of 48 hours after the declaration of the audited financial results of the Company, for the quarter and financial year ended March 31, 2026. Accordingly , all the Promoters, Directors and Designated Persons of he Company and their immediate relatives are being intimated to not to enter into any transaction involving trading in shares of the Company during the periods of closure of Trading Window. Further the date of Board Meeting at which the said results will be considered, shall be intimated in due course of time. Kindly take the information on record.

2026-03-25 16:51:37

Quarterly Financials

Consolidated Standalone
Particulars Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Revenue from Operations 19.96 22.26 20.40 24.04 21.56 26.02 26.14 25.80 31.02 32.31 30.17 56.79
YOY Revenue Growth % 14.21% 24.8% 9.9% 25.76% 7.99% 16.89% 28.15% 7.35% 43.91% 24.17% 15.41% 120.09%
Other Income 0.23 0.35 0.31 0.35 0.50 0.28 0.23 0.48 0.34 0.21 0.37 0.86
Total Income 20.19 22.61 20.71 24.38 22.06 26.30 26.37 26.29 31.36 32.51 30.54 57.65
Total Expenses + 22.41 22.05 21.89 25.70 22.84 26.29 27.52 28.12 35.31 33.06 28.60 56.99
Cost of Materials Consumed 2.56 5.00 4.69 1.98 3.38 5.14 5.22 4.33 6.46 6.63 5.43 3.62
Employee Benefit Expense 2.83 3.00 3.32 3.67 3.77 4.04 4.39 4.29 4.54 4.80 4.37 3.92
Other Expenses 3.53 3.33 4.10 3.38 3.36 3.68 4.52 6.05 6.83 4.81 4.20 6.17
Operating Profit -2.45 0.21 -1.49 -1.66 -1.28 -0.27 -1.38 -2.31 -4.28 -0.76 1.57 -0.20
OPM % -12.3% 0.9% -7.3% -6.9% -6% -1% -5.3% -9% -13.8% -2.4% 5.2% -0.3%
Profit Before Tax + -2.22 0.55 -1.17 -1.31 -0.79 0.01 -1.15 -1.83 -3.95 -0.55 1.94 0.67
Tax Expense -0.14 0.01 0.02 0.13 0.11 -0.09 0.00 0.08 0.18 0.09 0.10 -0.04
Tax % - 1.9% - - - -683.6% - - - - 5.2% -6.3%
Profit After Tax -2.08 0.54 -1.19 -1.44 -0.89 0.11 -1.15 -1.91 -4.13 -0.64 1.84 0.71
EPS (Basic) -3.80 1.04 -2.32 -2.48 -1.81 -0.50 -2.41 -4.03 -7.03 -2.02 3.17 0.88

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 108.99 88.25 75.47 70.94 56.88 58.45
YOY Revenue Growth % 23.49% 16.93% 6.4% 24.72% -2.7% -
Other Income 1.33 1.51 0.92 1.15 2.43 0.57
Total Income 110.32 89.76 76.40 72.09 59.30 59.03
Total Expenses + 117.23 92.48 76.29 70.24 60.13 61.48
Cost of Materials Consumed 21.15 15.05 14.01 13.86 10.32 10.49
Employee Benefit Expense 17.26 13.76 11.15 9.49 7.86 8.10
Other Expenses 21.07 14.18 13.23 11.75 10.04 11.19
Operating Profit -8.24 -4.22 -0.82 0.70 -3.26 -3.03
OPM % -7.6% -4.8% -1.1% 1% -5.7% -5.2%
Profit Before Exceptional -6.91 -2.72 0.11 1.85 -0.83 -2.45
Exceptional Items 0.00 0.00 0.00 0.00 -0.72 0.00
Profit Before Tax + -6.91 -2.72 0.11 1.85 -1.55 -2.45
Tax Expense 0.17 0.26 -0.01 -0.09 -0.80 -0.61
Tax % - - -9.5% -4.8% - -
Profit After Tax -7.08 -2.98 0.12 1.94 -0.75 -1.84
EPS (Basic) -13.98 -5.58 -0.33 2.53 -1.80 -4.86

Balance Sheet

Particulars Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 25.82 27.02 28.73 34.62 32.82 29.49
Property, Plant & Equipment 17.03 18.21 19.03 22.65 23.01 25.58
Capital Work in Progress 3.91 3.91 3.95 3.41 1.23 0.00
Non-Current Investments 2.01 1.83 1.89 1.97 0.00 1.14
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.00 0.00 0.00 0.00 0.74 0.75
Current Assets + 99.39 87.48 83.53 75.53 74.00 72.76
Inventories 50.38 40.02 38.74 37.70 35.41 30.42
Trade Receivables 25.49 28.40 27.74 19.51 19.48 24.92
Cash and Cash Equivalents 3.02 3.23 2.36 5.89 6.02 13.17
Current Investments 0.00 0.00 0.00 0.00 0.32 0.01
LIABILITIES & EQUITY
Total Equity 56.44 64.20 67.30 67.42 66.30 59.25
Equity Share Capital 5.04 5.04 5.04 5.04 5.04 5.04
Other Equity 47.00 54.73 57.65 58.06 57.61 54.21
Non-Current Liabilities 6.39 4.07 3.70 3.10 2.40 1.62
Current Liabilities 62.39 46.23 41.27 39.64 38.12 41.38
Total Liabilities 68.78 50.30 44.97 42.74 40.52 43.00

Cash Flow Statement

Particulars Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities -3.43 4.22 -2.77 5.07 -3.66 0.00
Cash from Investing Activities 2.55 -1.71 1.43 -3.52 -6.26 0.00
Cash from Financing Activities 0.67 -1.64 -2.19 -1.66 2.77 0.00
Net Increase/Decrease in Cash -0.21 0.87 -3.53 -0.12 -7.15 0.00